Yixuan Zhai1,2, Jiwei Bai1,3,4, Mingxuan Li1, Shuai Wang1, Chuzhong Li1,3,4,5, Xinting Wei2, Yazhuo Zhang1,3,4,5. 1. 1Beijing Neurosurgical Institute, Capital Medical University, Beijing. 2. 2Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou. 3. 3Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing. 4. 4China National Clinical Research Center for Neurological Diseases, Beijing; and. 5. 5Beijing Institute for Brain Disorders Brain Tumor Center, Beijing, China.
Abstract
OBJECTIVE: Chordoma shows poor patient prognosis because of its high recurrence rate. Even though many clinical factors and biomarkers are reported to be associated with prognosis, no prediction model has been applied clinically. Thus, the authors aim to derive and validate a prognostic nomogram to predict progression-free survival (PFS) of chordoma. METHODS: A total of 201 patients were randomly divided into a derivation group (151 cases) and a validation group (50 cases). The expression levels of biomarkers were quantified using tissue microarray analysis. A nomogram was established via univariate and multivariate Cox regression analysis in the derivation group. The predictive performance of the nomogram was then tested in the validation group. RESULTS: The mean follow-up interval was 57 months (range 26-107 months). One clinical factor and 3 biomarkers were confirmed to be associated with PFS, including degree of resection, E-cadherin, Ki-67, and VEGFA. The nomogram with these prognostic factors had areas under the receiver operating characteristic curve of 0.87 and 0.95 in the derivation group at 3 years and 5 years, respectively, compared with 0.87 and 0.84 in the validation group. Calibration and score-stratified survival curve were good in the derivation group and validation group, respectively. CONCLUSIONS: The established nomogram performs well for predicting the PFS of chordoma and for risk stratification, which could facilitate prognostic evaluation and follow-up.
RCT Entities:
OBJECTIVE:Chordoma shows poor patient prognosis because of its high recurrence rate. Even though many clinical factors and biomarkers are reported to be associated with prognosis, no prediction model has been applied clinically. Thus, the authors aim to derive and validate a prognostic nomogram to predict progression-free survival (PFS) of chordoma. METHODS: A total of 201 patients were randomly divided into a derivation group (151 cases) and a validation group (50 cases). The expression levels of biomarkers were quantified using tissue microarray analysis. A nomogram was established via univariate and multivariate Cox regression analysis in the derivation group. The predictive performance of the nomogram was then tested in the validation group. RESULTS: The mean follow-up interval was 57 months (range 26-107 months). One clinical factor and 3 biomarkers were confirmed to be associated with PFS, including degree of resection, E-cadherin, Ki-67, and VEGFA. The nomogram with these prognostic factors had areas under the receiver operating characteristic curve of 0.87 and 0.95 in the derivation group at 3 years and 5 years, respectively, compared with 0.87 and 0.84 in the validation group. Calibration and score-stratified survival curve were good in the derivation group and validation group, respectively. CONCLUSIONS: The established nomogram performs well for predicting the PFS of chordoma and for risk stratification, which could facilitate prognostic evaluation and follow-up.
Entities:
Keywords:
AUC = area under the ROC curve; GTR = gross-total resection; HR = hazard ratio; OS = overall survival; PFS = progression-free survival; PI = prognostic index; PR = partial resection; ROC = receiver operating characteristic; STR = subtotal resection; TMA = tissue microarray; chordoma; nomogram; oncology; progression-free survival
Authors: Cheng Jiang; Abhishek Bhattacharya; Joseph R Linzey; Rushikesh S Joshi; Sung Jik Cha; Sudharsan Srinivasan; Daniel Alber; Akhil Kondepudi; Esteban Urias; Balaji Pandian; Wajd N Al-Holou; Stephen E Sullivan; B Gregory Thompson; Jason A Heth; Christian W Freudiger; Siri Sahib S Khalsa; Donato R Pacione; John G Golfinos; Sandra Camelo-Piragua; Daniel A Orringer; Honglak Lee; Todd C Hollon Journal: Neurosurgery Date: 2022-03-30 Impact factor: 5.315
Authors: Geetika Nehra; Shannon Andrews; Joan Rettig; Michael N Gould; Jill D Haag; Steven P Howard; Robert G Thorne Journal: Sci Rep Date: 2021-03-18 Impact factor: 4.379
Authors: Franco Rubino; Christopher Alvarez-Breckenridge; Kadir Akdemir; Anthony P Conley; Andrew J Bishop; Wei-Lien Wang; Alexander J Lazar; Laurence D Rhines; Franco DeMonte; Shaan M Raza Journal: Front Oncol Date: 2022-09-29 Impact factor: 5.738